vs
Side-by-side financial comparison of Allstate (ALL) and Bristol Myers Squibb (BMY). Click either name above to swap in a different company.
Bristol Myers Squibb is the larger business by last-quarter revenue ($11.5B vs $922.0M, roughly 12.5× Allstate). Allstate runs the higher net margin — 266.6% vs 23.3%, a 243.3% gap on every dollar of revenue. On growth, Bristol Myers Squibb posted the faster year-over-year revenue change (11.0% vs 7.2%). Over the past eight quarters, Bristol Myers Squibb's revenue compounded faster (-3.0% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
ALL vs BMY — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $11.5B |
| Net Profit | $2.5B | $2.7B |
| Gross Margin | — | — |
| Operating Margin | -1400.3% | — |
| Net Margin | 266.6% | 23.3% |
| Revenue YoY | 7.2% | 11.0% |
| Net Profit YoY | — | 8.8% |
| EPS (diluted) | $9.25 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | $11.5B | ||
| Q4 25 | $17.3B | $12.5B | ||
| Q3 25 | $17.3B | $12.2B | ||
| Q2 25 | $16.6B | $12.3B | ||
| Q1 25 | $16.5B | $11.2B | ||
| Q4 24 | $16.5B | $12.3B | ||
| Q3 24 | $16.6B | $11.9B | ||
| Q2 24 | $15.7B | $12.2B |
| Q1 26 | $2.5B | $2.7B | ||
| Q4 25 | $3.8B | $1.1B | ||
| Q3 25 | $3.7B | $2.2B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $595.0M | $2.5B | ||
| Q4 24 | $1.9B | $72.0M | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $331.0M | $1.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.2% | ||
| Q3 25 | — | 71.9% | ||
| Q2 25 | — | 72.5% | ||
| Q1 25 | — | 72.9% | ||
| Q4 24 | — | 61.0% | ||
| Q3 24 | — | 75.1% | ||
| Q2 24 | — | 73.2% |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 25.5% | ||
| Q2 25 | — | 14.5% | ||
| Q1 25 | — | 26.5% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 14.1% | ||
| Q2 24 | — | 10.5% |
| Q1 26 | 266.6% | 23.3% | ||
| Q4 25 | 22.1% | 8.7% | ||
| Q3 25 | 21.7% | 18.0% | ||
| Q2 25 | 12.7% | 10.7% | ||
| Q1 25 | 3.6% | 21.9% | ||
| Q4 24 | 11.7% | 0.6% | ||
| Q3 24 | 7.2% | 10.2% | ||
| Q2 24 | 2.1% | 13.8% |
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | $0.54 | ||
| Q3 25 | $13.95 | $1.08 | ||
| Q2 25 | $7.76 | $0.64 | ||
| Q1 25 | $2.11 | $1.20 | ||
| Q4 24 | $7.07 | $0.05 | ||
| Q3 24 | $4.33 | $0.60 | ||
| Q2 24 | $1.13 | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $9.6B |
| Total DebtLower is stronger | — | $-42.2B |
| Stockholders' EquityBook value | $31.6B | — |
| Total Assets | $124.0B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $9.6B | ||
| Q4 25 | $4.9B | $10.2B | ||
| Q3 25 | $8.7B | $15.7B | ||
| Q2 25 | $9.6B | $12.6B | ||
| Q1 25 | $6.5B | $10.9B | ||
| Q4 24 | $4.5B | $10.3B | ||
| Q3 24 | $7.0B | $7.9B | ||
| Q2 24 | $5.3B | $6.3B |
| Q1 26 | — | $-42.2B | ||
| Q4 25 | $7.5B | $44.8B | ||
| Q3 25 | $8.1B | $48.7B | ||
| Q2 25 | $8.1B | $48.9B | ||
| Q1 25 | $8.1B | $49.5B | ||
| Q4 24 | $8.1B | $49.4B | ||
| Q3 24 | $8.1B | $49.5B | ||
| Q2 24 | $8.1B | $52.0B |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $18.5B | ||
| Q3 25 | $27.5B | $18.6B | ||
| Q2 25 | $24.0B | $17.4B | ||
| Q1 25 | $22.1B | $17.4B | ||
| Q4 24 | $21.4B | $16.3B | ||
| Q3 24 | $20.9B | $17.1B | ||
| Q2 24 | $18.6B | $17.0B |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $90.0B | ||
| Q3 25 | $120.4B | $96.9B | ||
| Q2 25 | $115.9B | $94.7B | ||
| Q1 25 | $115.2B | $92.4B | ||
| Q4 24 | $111.6B | $92.6B | ||
| Q3 24 | $113.7B | $93.7B | ||
| Q2 24 | $108.4B | $94.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | 2.43× | ||
| Q3 25 | 0.29× | 2.63× | ||
| Q2 25 | 0.34× | 2.81× | ||
| Q1 25 | 0.37× | 2.85× | ||
| Q4 24 | 0.38× | 3.03× | ||
| Q3 24 | 0.39× | 2.89× | ||
| Q2 24 | 0.43× | 3.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
